Abstract
Purpose: To examine international technology development of fibrates based on a cross-database quantitative patent review and to describe the evolution pathway for fibrates by means of a technology roadmap. Methods: The patent data were collected in March 2013 from United States Patent and Trademark Office (USPTO), European Patent Office (EPO) and China Intellectual Property Right Net (CNIPR) to broadly represent global patent activities. Results: This study selected and examined 84 patents from USPTO, 41 patents from EPO and 39 patents from CNIPR. It showed that most of the fibrate patents were fenofibrate patents (41.67 % at USPTO, 46.34 % at EPO and 33.33 % at CNIPR). The number of preparation patents (44 at USPTO, 24 at EPO and 17 at CNIPR) and combination patents (23 at USPTO, 11 at EPO and 15 at CNIPR) was obviously larger than other types of fibrate patents. The technology roadmap shows that new monomersor derivatives of fibrates can drive fibrate evolution into a new cycle of application-synthesiscombination- preparation. Conclusion: This study provides a comprehensive picture of fibrate development. It will aid researchers, entrepreneurs, investors and policymakers to identify foci for fibrate research and ensure better decision-making.
Highlights
Hypertriglyceridemia (HTG) is a major risk factor in many cardiovascular and cerebrovascular diseases, including coronary heart disease, stroke, atherosclerosis [1,2]
To become major players in fibrate industry, local pharmaceutical companies in China should significantly boost their research and development (R&D) efforts in fibrate technology. It is critical for researchers and manufacturers to be aware of publications and patents in this field across different laboratories, companies and countries to map the development of fibrates and of core and new fibrate technologies
This study aims to examine the international technology development of fibrates based on a cross-database quantitative patent review and to describe the evolution pathway for fibrates by means of a technology roadmap
Summary
Hypertriglyceridemia (HTG) is a major risk factor in many cardiovascular and cerebrovascular diseases, including coronary heart disease, stroke, atherosclerosis [1,2]. More and more research has revealed elevated triglyceride (TG) to be an independent risk factor for cardiovascular disease [3,4]. To become major players in fibrate industry, local pharmaceutical companies in China should significantly boost their research and development (R&D) efforts in fibrate technology. It is critical for researchers and manufacturers to be aware of publications and patents in this field across different laboratories, companies and countries to map the development of fibrates and of core and new fibrate technologies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
